ZA200206073B - Antiviral azaindole derivatives. - Google Patents
Antiviral azaindole derivatives. Download PDFInfo
- Publication number
- ZA200206073B ZA200206073B ZA200206073A ZA200206073A ZA200206073B ZA 200206073 B ZA200206073 B ZA 200206073B ZA 200206073 A ZA200206073 A ZA 200206073A ZA 200206073 A ZA200206073 A ZA 200206073A ZA 200206073 B ZA200206073 B ZA 200206073B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- compound
- alkynyl
- carbon
- alkyl
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims description 12
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 40
- -1 C.-C Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 208000030507 AIDS Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 105
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000000304 alkynyl group Chemical group 0.000 claims 29
- 125000003342 alkenyl group Chemical group 0.000 claims 27
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 22
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 229910052792 caesium Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- 229960005475 antiinfective agent Drugs 0.000 claims 3
- 239000004599 antimicrobial Substances 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000006329 ethyl amino carbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 229910019567 Re Re Inorganic materials 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 102100028651 Tenascin-N Human genes 0.000 claims 1
- 101710087911 Tenascin-N Proteins 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 7
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 7
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 3
- DMPXDLRQZYXVHL-UHFFFAOYSA-N 2,5-dihydroxy-3,6-bis[6-(3-methylbut-2-enyl)-1h-indol-3-yl]cyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC1=CC=C2C(C=3C(=O)C(O)=C(C(C=3O)=O)C=3C4=CC=C(C=C4NC=3)CC=C(C)C)=CNC2=C1 DMPXDLRQZYXVHL-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 229960005319 delavirdine Drugs 0.000 description 2
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- 239000004030 hiv protease inhibitor Substances 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- XNQAJERZSLDENY-UHFFFAOYSA-N semicochliodinol A Chemical compound C1=CC=C2C(C=3C(=O)C(O)=C(C(C=3O)=O)C3=CNC4=CC=C(C=C43)CC=C(C)C)=CNC2=C1 XNQAJERZSLDENY-UHFFFAOYSA-N 0.000 description 2
- RXCOGDYOZQGGMK-UHFFFAOYSA-N (3,4-diaminophenyl)-phenylmethanone Chemical compound C1=C(N)C(N)=CC=C1C(=O)C1=CC=CC=C1 RXCOGDYOZQGGMK-UHFFFAOYSA-N 0.000 description 1
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical class C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical class N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical class C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 1
- YGBYVNQFNMXDJM-UHFFFAOYSA-N 1h-indazole-5-carbonitrile Chemical compound N#CC1=CC=C2NN=CC2=C1 YGBYVNQFNMXDJM-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- PMBKVWCLVTYNAG-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical class C1=CN=C2C(C(=O)N)=CNC2=C1 PMBKVWCLVTYNAG-UHFFFAOYSA-N 0.000 description 1
- HNGJGZFTQRJUIF-UHFFFAOYSA-N 2,5-dihydroxy-3,6-bis(1h-indol-3-yl)cyclohexa-2,5-diene-1,4-dione Chemical compound C1=CC=C2C(C3=C(O)C(=O)C(C=4C5=CC=CC=C5NC=4)=C(C3=O)O)=CNC2=C1 HNGJGZFTQRJUIF-UHFFFAOYSA-N 0.000 description 1
- FBCZWQNVHNIQOD-UHFFFAOYSA-N 2-piperazin-1-yl-1h-indole Chemical class C1CNCCN1C1=CC2=CC=CC=C2N1 FBCZWQNVHNIQOD-UHFFFAOYSA-N 0.000 description 1
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 1
- RWHZLSHOGJONCU-UHFFFAOYSA-N 5h-indolo[3,2-b][1,5]benzothiazepine Chemical class C1=NC2=CC=CC=C2SC2=C1NC1=CC=CC=C21 RWHZLSHOGJONCU-UHFFFAOYSA-N 0.000 description 1
- LLGMYKPLPYSPKQ-UHFFFAOYSA-N 6-chloro-1h-pyrrolo[2,3-b]pyridine-5-carbonitrile Chemical class C1=C(C#N)C(Cl)=NC2=C1C=CN2 LLGMYKPLPYSPKQ-UHFFFAOYSA-N 0.000 description 1
- CHVRKRDEYKTBKI-UHFFFAOYSA-N 6-oxo-1,2,3,7-tetrahydropyrrolo[2,3-b]pyridine-5-carbonitrile Chemical class C1=C(C#N)C(O)=NC2=C1CCN2 CHVRKRDEYKTBKI-UHFFFAOYSA-N 0.000 description 1
- QKEBGAUJUHZNNU-UHFFFAOYSA-N 9h-pyrrolo[2,3-f]quinoxaline Chemical class N1=CC=NC2=C(NC=C3)C3=CC=C21 QKEBGAUJUHZNNU-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical class N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- YHDKHLAZFLOSBC-UHFFFAOYSA-N C1=CC=C2C(NC(=O)O)=CNC2=N1 Chemical class C1=CC=C2C(NC(=O)O)=CNC2=N1 YHDKHLAZFLOSBC-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- ZNWDZJLADJYDNK-UHFFFAOYSA-N N1=CC2=NC=CC=C2C2=NC(=O)C=CC2=N1 Chemical compound N1=CC2=NC=CC=C2C2=NC(=O)C=CC2=N1 ZNWDZJLADJYDNK-UHFFFAOYSA-N 0.000 description 1
- GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- XDNADZYPWVQFRI-UHFFFAOYSA-N [1]benzofuro[2,3-h]quinoline Chemical class C1=CC=NC2=C3C4=CC=CC=C4OC3=CC=C21 XDNADZYPWVQFRI-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 150000001927 cycloarenes Chemical class 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- LRELZOWQHCZJTO-UHFFFAOYSA-N ethyl n-(2-bromophenyl)carbamate Chemical class CCOC(=O)NC1=CC=CC=C1Br LRELZOWQHCZJTO-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GYGNNRWBBHJVNM-UHFFFAOYSA-N n-(1h-1,2-benzodiazepin-7-yl)hydroxylamine Chemical class N1N=CC=CC2=CC(NO)=CC=C21 GYGNNRWBBHJVNM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 125000002734 organomagnesium group Chemical group 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical class CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- JWHQWQQROAZMII-UHFFFAOYSA-N semicochliodinol B Chemical compound C1=CC=C2C(C=3C(=O)C(O)=C(C(C=3O)=O)C=3C4=CC=C(C=C4NC=3)CC=C(C)C)=CNC2=C1 JWHQWQQROAZMII-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18400400P | 2000-02-22 | 2000-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206073B true ZA200206073B (en) | 2003-10-30 |
Family
ID=22675206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206073A ZA200206073B (en) | 2000-02-22 | 2002-07-30 | Antiviral azaindole derivatives. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20020061892A1 (enExample) |
| EP (1) | EP1257276B1 (enExample) |
| JP (1) | JP3868814B2 (enExample) |
| KR (1) | KR100496574B1 (enExample) |
| CN (1) | CN1404392A (enExample) |
| AR (1) | AR029469A1 (enExample) |
| AT (1) | ATE314072T1 (enExample) |
| AU (2) | AU2001232895B2 (enExample) |
| BR (1) | BRPI0108485B1 (enExample) |
| CA (1) | CA2400700C (enExample) |
| CO (1) | CO5271657A1 (enExample) |
| CY (1) | CY1107460T1 (enExample) |
| DE (1) | DE60116260T2 (enExample) |
| DK (1) | DK1257276T3 (enExample) |
| EG (1) | EG24669A (enExample) |
| ES (1) | ES2254367T3 (enExample) |
| HU (1) | HU229992B1 (enExample) |
| IL (1) | IL150734A0 (enExample) |
| MX (1) | MXPA02008113A (enExample) |
| MY (1) | MY128458A (enExample) |
| NO (1) | NO323564B1 (enExample) |
| NZ (1) | NZ520317A (enExample) |
| PE (1) | PE20020786A1 (enExample) |
| PL (1) | PL357434A1 (enExample) |
| PT (1) | PT1257276E (enExample) |
| RU (1) | RU2259372C2 (enExample) |
| TR (1) | TR200201961T2 (enExample) |
| TW (1) | TWI293629B (enExample) |
| UY (1) | UY26593A1 (enExample) |
| WO (1) | WO2001062255A1 (enExample) |
| ZA (1) | ZA200206073B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20030207910A1 (en) * | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| PL364279A1 (en) * | 2001-02-02 | 2004-12-13 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
| US20040162298A1 (en) * | 2002-02-23 | 2004-08-19 | Hsu-Tso Ho | Method of treating HIV infection by preventing interaction of CD4 and gp120 |
| US20040063744A1 (en) * | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US20050075364A1 (en) * | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ｒｅｔ調節剤の開発のための化合物および方法 |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| CN1953985B (zh) * | 2004-03-15 | 2010-06-09 | 布里斯托尔-迈尔斯斯奎布公司 | 哌嗪和取代的哌啶抗病毒药物的前药 |
| US20050252408A1 (en) * | 2004-05-17 | 2005-11-17 | Richardson H W | Particulate wood preservative and method for producing same |
| DK1753764T3 (da) | 2004-06-09 | 2009-02-16 | Glaxo Group Ltd | Pyrrolopyridin-derivater |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US7183284B2 (en) * | 2004-12-29 | 2007-02-27 | Bristol-Myers Squibb Company | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents |
| US7601715B2 (en) | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| EP1910573B1 (en) | 2005-07-22 | 2013-09-04 | CytoDyn, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US7598380B2 (en) * | 2005-08-03 | 2009-10-06 | Bristol-Myers Squibb Company | Method of preparation of azaindole derivatives |
| US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
| US7622466B2 (en) * | 2005-11-18 | 2009-11-24 | Hoffman-La Roche Inc. | Azaindole-2-carboxamide derivatives |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| MX2009013431A (es) * | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| WO2009011912A1 (en) * | 2007-07-18 | 2009-01-22 | Bristol-Myers Squibb Company | A composition for treating hiv comprising virus-like particles |
| CA2712701A1 (en) | 2008-01-31 | 2009-08-06 | Henning Steinhagen | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| CN102143739B (zh) * | 2008-09-04 | 2014-12-17 | 百时美施贵宝公司 | 用于最优化传递hiv附着抑制剂的稳定的药用组合物 |
| CA2738573C (en) | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
| US8912195B2 (en) | 2010-12-02 | 2014-12-16 | Bristol-Myers Squibb Company | Alkyl amides as HIV attachment inhibitors |
| PE20141360A1 (es) | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| WO2012142080A1 (en) | 2011-04-12 | 2012-10-18 | Bristol-Myers Squibb Company | Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
| EP2751119B1 (en) | 2011-08-29 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| WO2013033059A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN102746295B (zh) * | 2012-06-20 | 2014-10-15 | 上海阿达玛斯试剂有限公司 | 4位取代-7-氮杂吲哚的制备方法 |
| WO2014025854A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Piperidine amide derivatives as hiv attachment inhibitors |
| ES2616432T3 (es) | 2012-08-09 | 2017-06-13 | VIIV Healthcare UK (No.5) Limited | Derivados de alquenos tricíclicos como inhibidores de la unión del VIH |
| CN109528749B (zh) * | 2017-09-22 | 2023-04-28 | 上海交通大学医学院附属瑞金医院 | 长链非编码rna-h19在制备治疗垂体瘤药物中的用途 |
| CA3196620A1 (en) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
| CN118515629A (zh) * | 2020-11-24 | 2024-08-20 | 中国人民解放军海军军医大学 | 一类取代苯甲酰哌嗪类化合物及其应用 |
| CN115855899B (zh) * | 2022-11-24 | 2025-06-10 | 常熟理工学院 | 一种荧光探针检测二氧化硫衍生物的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9203454A (es) * | 1989-12-28 | 1992-08-01 | Upjohn Co | Compuestos anti sida diaromaticos substituidos. |
| US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
-
2001
- 2001-01-18 US US09/765,189 patent/US20020061892A1/en not_active Abandoned
- 2001-01-19 IL IL15073401A patent/IL150734A0/xx unknown
- 2001-01-19 JP JP2001561320A patent/JP3868814B2/ja not_active Expired - Fee Related
- 2001-01-19 RU RU2002125494/04A patent/RU2259372C2/ru not_active IP Right Cessation
- 2001-01-19 KR KR10-2002-7010888A patent/KR100496574B1/ko not_active Expired - Fee Related
- 2001-01-19 HU HUP0301508A patent/HU229992B1/hu not_active IP Right Cessation
- 2001-01-19 MX MXPA02008113A patent/MXPA02008113A/es active IP Right Grant
- 2001-01-19 EP EP01904970A patent/EP1257276B1/en not_active Expired - Lifetime
- 2001-01-19 DE DE60116260T patent/DE60116260T2/de not_active Expired - Lifetime
- 2001-01-19 TR TR2002/01961T patent/TR200201961T2/xx unknown
- 2001-01-19 ES ES01904970T patent/ES2254367T3/es not_active Expired - Lifetime
- 2001-01-19 NZ NZ520317A patent/NZ520317A/en not_active IP Right Cessation
- 2001-01-19 CA CA2400700A patent/CA2400700C/en not_active Expired - Fee Related
- 2001-01-19 AT AT01904970T patent/ATE314072T1/de active
- 2001-01-19 AU AU2001232895A patent/AU2001232895B2/en not_active Ceased
- 2001-01-19 PT PT01904970T patent/PT1257276E/pt unknown
- 2001-01-19 BR BRPI0108485A patent/BRPI0108485B1/pt not_active IP Right Cessation
- 2001-01-19 PL PL01357434A patent/PL357434A1/xx not_active Application Discontinuation
- 2001-01-19 WO PCT/US2001/002009 patent/WO2001062255A1/en not_active Ceased
- 2001-01-19 DK DK01904970T patent/DK1257276T3/da active
- 2001-01-19 CN CN01805504A patent/CN1404392A/zh active Pending
- 2001-01-19 AU AU3289501A patent/AU3289501A/xx active Pending
- 2001-02-06 MY MYPI20010516A patent/MY128458A/en unknown
- 2001-02-07 TW TW090102639A patent/TWI293629B/zh not_active IP Right Cessation
- 2001-02-19 AR ARP010100742A patent/AR029469A1/es active IP Right Grant
- 2001-02-19 EG EG20010152A patent/EG24669A/xx active
- 2001-02-20 CO CO01013156A patent/CO5271657A1/es not_active Application Discontinuation
- 2001-02-21 UY UY26593A patent/UY26593A1/es not_active IP Right Cessation
- 2001-02-22 PE PE2001000190A patent/PE20020786A1/es not_active Application Discontinuation
-
2002
- 2002-07-30 ZA ZA200206073A patent/ZA200206073B/en unknown
- 2002-08-21 NO NO20023981A patent/NO323564B1/no not_active IP Right Cessation
-
2006
- 2006-03-27 CY CY20061100420T patent/CY1107460T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2303038C2 (ru) | Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе | |
| DK2801576T3 (en) | Composition and antiviral activity in substituted azaindoleoxoeddikepiperazinderivater | |
| DE60116260T2 (de) | Antivirale azaindolderivate | |
| ZA200409504B (en) | Indole, azaindole and relate heterocyclic 4-alkenyl piperidine amides | |
| US6476034B2 (en) | Antiviral azaindole derivatives | |
| US20040110785A1 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| JP2007516205A (ja) | インドール、アザインドール、および関連するヘテロ環状ｎ−置換ピペラジン誘導体 | |
| KR20250166103A (ko) | 종양 치료용 약제학적 조성물 | |
| HK1202530B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| HK1072731B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| HK1174037B (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| HK1052132B (en) | Antiviral azaindole derivatives |